Allianz Asset Management’s PTC Therapeutics PTCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$504K Hold
7,400
﹤0.01% 1942
2026
Q1
$504K Sell
7,400
-7,185
-49% -$509K ﹤0.01% 1840
2025
Q4
$1.11M Buy
14,585
+6,285
+76% +$457K ﹤0.01% 1688
2025
Q3
$509K Buy
8,300
+700
+9% +$36.5K ﹤0.01% 1837
2025
Q2
$371K Sell
7,600
-5,300
-41% -$252K ﹤0.01% 1881
2025
Q1
$657K Sell
12,900
-4,700
-27% -$235K ﹤0.01% 1792
2024
Q4
$794K Buy
+17,600
New +$753K ﹤0.01% 1715
2022
Q3
Sell
-18,495
Closed -$741K 2074
2022
Q2
$741K Sell
18,495
-53,180
-74% -$1.86M ﹤0.01% 1778
2022
Q1
$2.67M Hold
71,675
﹤0.01% 1483
2021
Q4
$2.86M Buy
+71,675
New +$2.74M ﹤0.01% 1470
2021
Q2
Sell
-22,800
Closed -$1.08M 2463
2021
Q1
$1.08M Sell
22,800
-61
-0.3% -$3.62K ﹤0.01% 1613
2020
Q4
$1.4M Sell
22,861
-492
-2% -$29K ﹤0.01% 1405
2020
Q3
$1.09M Sell
23,353
-25,889
-53% -$1.27M ﹤0.01% 1408
2020
Q2
$2.5M Sell
49,242
-27,660
-36% -$1.36M ﹤0.01% 1520
2020
Q1
$3.43M Sell
76,902
-64,328
-46% -$3.24M ﹤0.01% 1323
2019
Q4
$6.78M Buy
141,230
+768
+0.5% +$32.6K 0.01% 1341
2019
Q3
$4.77M Buy
140,462
+48,340
+52% +$2.1M ﹤0.01% 1469
2019
Q2
$4.15M Buy
92,122
+56,008
+155% +$2.21M ﹤0.01% 1588
2019
Q1
$1.36M Sell
36,114
-42,234
-54% -$1.42M ﹤0.01% 1977
2018
Q4
$2.66M Buy
78,348
+24,763
+46% +$890K ﹤0.01% 1651
2018
Q3
$2.52M Sell
53,585
-2,000
-4% -$82.8K ﹤0.01% 1856
2018
Q2
$1.88M Buy
55,585
+30,285
+120% +$944K ﹤0.01% 1973
2018
Q1
$685K Buy
+25,300
New +$641K ﹤0.01% 2313

Other funds holding PTCT

Allianz Asset Management's PTCT Position: Q2 2026 in Review

Allianz Asset Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 7,400 shares worth $504K. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

Allianz Asset Management first reported a position in PTCT in Q1 2018 and has held it in 23 quarters since. The position peaked at $6.78M in Q4 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Allianz Asset Management held 7,400 shares of PTC Therapeutics worth $504K as of Q2 2026.
  • Allianz Asset Management left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #1942 holding.
  • Allianz Asset Management first reported a position in PTC Therapeutics in Q1 2018 and has held it in 23 quarters since.
  • Allianz Asset Management's PTC Therapeutics position peaked at $6.78M in Q4 2019.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.